1. Home
  2. URI vs ALNY Comparison

URI vs ALNY Comparison

Compare URI & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo United Rentals Inc.

URI

United Rentals Inc.

HOLD

Current Price

$744.74

Market Cap

52.0B

ML Signal

HOLD

Logo Alnylam Pharmaceuticals Inc.

ALNY

Alnylam Pharmaceuticals Inc.

HOLD

Current Price

$319.95

Market Cap

42.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
URI
ALNY
Founded
1997
2002
Country
United States
United States
Employees
N/A
115
Industry
Diversified Commercial Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
52.0B
42.1B
IPO Year
1998
2004

Fundamental Metrics

Financial Performance
Metric
URI
ALNY
Price
$744.74
$319.95
Analyst Decision
Buy
Strong Buy
Analyst Count
13
29
Target Price
$968.83
$467.68
AVG Volume (30 Days)
537.5K
882.9K
Earning Date
04-29-2026
01-01-0001
Dividend Yield
1.07%
N/A
EPS Growth
N/A
206.88
EPS
38.61
2.33
Revenue
$16,099,000,000.00
$1,037,418,000.00
Revenue This Year
$7.18
$52.78
Revenue Next Year
$7.22
$31.86
P/E Ratio
$19.17
$136.66
Revenue Growth
4.91
22.88
52 Week Low
$525.91
$205.87
52 Week High
$1,021.47
$495.55

Technical Indicators

Market Signals
Indicator
URI
ALNY
Relative Strength Index (RSI) 33.50 42.63
Support Level $682.03 $309.57
Resistance Level $848.49 $333.70
Average True Range (ATR) 27.20 8.98
MACD -10.79 0.91
Stochastic Oscillator 12.73 41.07

Price Performance

Historical Comparison
URI
ALNY

About URI United Rentals Inc.

United Rentals is the world's largest equipment rental company, principally operating in the US and Canada. It has 16% share in a highly fragmented market serving general industrial (49%), commercial construction (46%), and residential construction (5%). The company operates a $21 billion fleet of equipment, including aerial platforms, forklifts, excavators, trucks, power generators, and various other materials serving local and national accounts from nearly 1,600 locations in North America and 100 abroad. It has pursued a strategy of bundling specialty rental capabilities to offer its customers more advanced solutions in addition to its core equipment rental business, supporting its ambitions to become a one-stop shop for customers and enhance and maintain its margin profile.

About ALNY Alnylam Pharmaceuticals Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway in cells that enables sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Share on Social Networks: